Finance

Beta
Lists
TGTR:TLV
Together Pharma Ltd
ILA 240.00
-2.56%
(-6.30) 1D
Jun 1, 2:29:11 PM GMT+3  ·   ILA
All symbols
SymbolPriceChange% Change
Generating top insights for TGTR...
Open
ILA 246.30
Mkt. cap
42.73M
Avg. vol.
5.54K
Volume
0.00
P/E ratio
19.84
52-wk high
ILA 415.00
52-wk low
ILA 239.90
EPS
ILA 0.12
Shares outstanding
17.35M
No. of employees
210
Open
ILA 246.30
Mkt. cap
42.73M
Avg. vol.
5.54K
Volume
0.00
P/E ratio
19.84
52-wk high
ILA 415.00
52-wk low
ILA 239.90
EPS
ILA 0.12
Shares outstanding
17.35M
No. of employees
210
News stories
From sources across the web
About Together Pharma Ltd
CEONissim Bracha
Employees210
Founded1991
HeadquartersRamat Gan, Tel Aviv District, Israel
SectorPharmaceutical industry
Previous reportsAll values in ILS
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in ILS
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
31.78M
31.78M
23.03M
23.03M
Cost of goods sold
22.40M
22.40M
16.67M
16.67M
Cost of revenue
22.40M
22.40M
16.67M
16.67M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.62M
4.62M
3.51M
3.51M
Operating expense
4.62M
4.62M
3.51M
3.51M
Total operating expenses
27.02M
27.02M
20.18M
20.18M
Operating income
4.76M
4.76M
2.85M
2.85M
Other non operating income
-
-
-375.50K
-375.50K
EBT including unusual items
2.06M
2.06M
375.00K
375.00K
EBT excluding unusual items
2.06M
2.06M
375.00K
375.00K
Income tax expense
1.18M
1.18M
293.00K
293.00K
Effective tax rate
57.46%
57.46%
78.13%
78.13%
Other operating expenses
-
-
-
-
Net income
487.00K
487.00K
469.00K
469.00K
Net profit margin
1.53%
1.53%
2.04%
2.04%
Earnings per share
-
-
-
-
Interest and investment income
98.50K
98.50K
-
-
Interest expense
-2.80M
-2.80M
-665.50K
-665.50K
Net interest expenses
-2.70M
-2.70M
-665.50K
-665.50K
Depreciation and amortization charges
-
-
-
-
EBITDA
6.50M
6.50M
4.14M
4.14M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more